These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23795818)

  • 1. Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.
    Salunke DB; Connelly SW; Shukla NM; Hermanson AR; Fox LM; David SA
    J Med Chem; 2013 Jul; 56(14):5885-900. PubMed ID: 23795818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.
    Agnihotri G; Crall BM; Lewis TC; Day TP; Balakrishna R; Warshakoon HJ; Malladi SS; David SA
    J Med Chem; 2011 Dec; 54(23):8148-60. PubMed ID: 22007676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
    Salunke DB; Shukla NM; Yoo E; Crall BM; Balakrishna R; Malladi SS; David SA
    J Med Chem; 2012 Apr; 55(7):3353-63. PubMed ID: 22385476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.
    Willems MM; Zom GG; Khan S; Meeuwenoord N; Melief CJ; van der Stelt M; Overkleeft HS; Codée JD; van der Marel GA; Ossendorp F; Filippov DV
    J Med Chem; 2014 Aug; 57(15):6873-8. PubMed ID: 25019313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
    Lu BL; Williams GM; Verdon DJ; Dunbar PR; Brimble MA
    J Med Chem; 2020 Mar; 63(5):2282-2291. PubMed ID: 31418565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response.
    Wijayadikusumah AR; Zeng W; McQuilten HA; Wong CY; Jackson DC; Chua BY
    Mol Pharm; 2019 May; 16(5):2037-2047. PubMed ID: 30924661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models.
    Halliday A; Turner JD; Guimarães A; Bates PA; Taylor MJ
    Parasit Vectors; 2016 Feb; 9():96. PubMed ID: 26897363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, evaluation and molecular dynamics study of human toll-like receptor 2/6 specific monoacyl lipopeptides as candidate immunostimulants.
    Zhu Y; Liu B; Chen Z; Wang X; Wang Y; Zhang W; Wang S; Zhang M; Li Y
    Bioorg Chem; 2023 Dec; 141():106823. PubMed ID: 37708825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8
    Sekiya T; Yamagishi J; Gray JHV; Whitney PG; Martinelli A; Zeng W; Wong CY; Sugimoto C; Jackson DC; Chua BY
    Biomaterials; 2017 Aug; 137():61-72. PubMed ID: 28544973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response.
    Mao L; Liu C; Liu JY; Jin ZL; Jin Z; Xue RY; Feng R; Li GC; Deng Y; Cheng H; Zou QM; Li HB
    Front Immunol; 2022; 13():833418. PubMed ID: 35356002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
    Kumar S; Sunagar R; Gosselin E
    Front Immunol; 2019; 10():1144. PubMed ID: 31191528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR2 agonists and their structure-activity relationships.
    Lu BL; Williams GM; Brimble MA
    Org Biomol Chem; 2020 Jul; 18(27):5073-5094. PubMed ID: 32582902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.
    Chua BY; Zeng W; Jackson DC
    Methods Mol Biol; 2008; 494():247-61. PubMed ID: 18726578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2).
    Shakhov AN; Singh VK; Bone F; Cheney A; Kononov Y; Krasnov P; Bratanova-Toshkova TK; Shakhova VV; Young J; Weil MM; Panoskaltsis-Mortari A; Orschell CM; Baker PS; Gudkov A; Feinstein E
    PLoS One; 2012; 7(3):e33044. PubMed ID: 22479357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
    Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
    Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
    Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
    Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of
    Zhou Y; Banday AH; Hruby VJ; Cai M
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31569697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.
    Akazawa T; Ohashi T; Wijewardana V; Sugiura K; Inoue N
    Cancer Sci; 2018 May; 109(5):1319-1329. PubMed ID: 29575556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.